Drugs / 4D-150
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05197270 | Dec 2021 → Mar 2027 expected | wet macular degeneration | 4D Molecular Therapeutics | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05930561 | Aug 2023 → Feb 2029 expected | diabetic macular edema | 4D Molecular Therapeutics | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07064759 | Jul 2025 → Nov 2028 expected | wet macular degeneration | 4D Molecular Therapeutics | Recruiting | No outcome recorded |
| Phase 3 | NCT06864988 | Mar 2025 → Jun 2027 expected | wet macular degeneration | 4D Molecular Therapeutics | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-10-31 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Enters into Licensing Agreement for Ophthalmic Gene Therapy Drug Candidate 4D-150 (Anti-VEGF agent) otsuka.co.jp ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4D-150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05930561 ↗ |
| Action | Inhibit | “a recombinant protein that inhibits VEGF-A, VEGF-B, and PlGF, and a microRNA sequence that inhibits expression of VEGF-C” PMID 39620832 ↗ Dec 2024 |
| Modality | Gene therapy (AAV / viral vector) | “4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept” NCT05197270 ↗ |
| Route | Intravitreal | “single dose IVT injection” NCT05197270 ↗ |